MMSI — Merit Medical Systems, Inc.
Is MMSI overbought or oversold? Here is the current MarketMoodz read.
Merit Medical Systems, Inc. (MMSI) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $85.37. The rating moved from Overbought to Oversold on October 1, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$85.37
- Last changeMoved from Overbought to Oversold on October 1, 2026
- SectorHealthcare
- IndustryMedical Instruments & Supplies
See all oversold Healthcare stocks →
AI analysis
Merit Medical Systems exhibits a resilient consumables-driven business with diversified procedural product lines and consistent free cash flow, supported by strategic M&A and international expansion. Near-term performance will be influenced by hospital procedure volumes, reimbursement dynamics, and macro risk sentiment; sustained execution on integration, new product adoption, and supply-chain efficiency will be the primary drivers of outperformance. Key downside scenarios include meaningful reimbursement shifts, regulatory recalls, or a prolonged pullback in elective procedure demand.
Key factors
- Recurring consumables revenue from disposable procedural products provides steady revenue and margin resiliency versus capital-equipment driven names
- Diversified product portfolio across interventional cardiology, radiology, endoscopy and specialty vascular access supports cross-selling and end-market exposure
- History of disciplined M&A and integration that has expanded product breadth and international footprint, supporting incremental revenue streams
- Solid free cash flow generation and balance-sheet flexibility to fund organic growth, bolt-on acquisitions, and share repurchases
- Defensive demand profile for many procedural consumables supports relative stability in a risk-off market environment
- Operational improvements and nearshoring/supply-chain optimization have reduced prior inventory and sourcing vulnerabilities
Risks
- Reimbursement pressure and changes in Medicare/Medicare Advantage policy could compress end-market procedure volumes or pricing for some product lines
- Hospital capital budget constraints and elective procedure slowdowns could reduce demand for certain devices and larger-ticket systems
- Competitive pressure from larger medtech firms and niche innovators could erode share or force margin concessions
- Regulatory or quality-related recalls would have outsized financial and reputational impact on a consumables-heavy business
- Macroeconomic risk-off and weaker healthcare spending in key international markets could slow growth
- Foreign exchange volatility given international sales exposure could pressure reported results
- Execution risk on integrating acquisitions or scaling new product launches
- Supplier concentration or renewed global supply-chain disruption could increase costs or create product shortages
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for MMSI — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.